The Osteopore Ltd (ASX: OSX) share price rocketed as much as 270% higher at one point today, after the company announced it has signed a distribution agreement that opens up the potentially lucrative US market.
Image source: Getty Images
Why is the Osteopore share price surging?
Earlier this morning, Osteopore announced that the company has signed a non-exclusive, 2-year agreement with established US market leader Bioplate Inc. The agreement will see Bioplate help Osteopore sell its patented 3D printed, bioresorbable products for cranial and neurosurgery procedures. The distribution agreement covers 6 states in the US market and Bioplate will cover all technical support requirements for Osteopore's products.
The agreement with Bioplate is Osteopore's first distribution agreement since the company's IPO in 2019. Bioplate has over 20 years of experience in providing cranial fixation solutions and will provide Osteopore with an established network of health professionals, hospitals and health services in the US.
According to Osteopore, the graft substitute market is worth around US$4 billion, with sales of permanent implants estimated at over US$100 million annually. Osteopore believes that penetrating the US market is a key strategic objective, with US demand accounting for a large portion of the global demand.
What does Osteopore do?
Osteopore is an Australian and Singapore-based medical technology company that has commercialised a range of patented, 3D printed bioresorbable products. These 3D printed implants act as a scaffold for bone growth and can be used across various surgeries. As opposed to traditional bone grafts, Osteopore's implants naturally dissolve over time, leaving only health bone tissue.
According to Osteopore, the company's protective implants can reduce post-surgery complications by reducing the risk of secondary infections. All 3 of Osteopore's products (Osteoplug, Osteomesh and Osteostrip) have received FDA approval in the US and are being sold to hospitals around the globe.
Earlier this year, Osteopore reported a 60% increase in revenue for the quarter ending March 2020. The company generated $321,00 in revenue for the quarter whilst also receiving approval from the Australian Therapeutic Goods Administration for several of its craniofacial products.
Foolish takeaway
Following a pause in trading mid-morning, shares in Osteopore resumed trading and are up more than 150% at the time of writing. The Osteopore share price hit an intra-day high of $1.49 earlier, representing a gain of more than 270% for the day.
